20.62USD-3.96%Mkt Cap: 1.35B USDP/E: —Last update: 2026-06-01
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a cl…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap1.35B USD
Enterprise Value890.75M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-137.95M USD
Revenue/Share—
Last Price20.62 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees103
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.99
PEG—
EV/EBITDA-5.12
EV/Revenue—
P/S—
P/B2.77
EPS (TTM)-2.77
EPS (Forward)-3.63
52W Range
8.48077% of range24.25
52W High24.25 USD
52W Low8.480 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-34.36%
ROA-32.01%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-106.83M USD
CapEx (TTM)280.00K USD
FCF Margin—
FCF Yield-5.07%
Net Debt-538.31M USD
Net Debt/EBITDA3.10
Balance Sheet
Debt/Equity0.00
Current Ratio13.85
Quick Ratio13.72
Book Value/Sh7.841 USD
Cash/Share8.215 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Target (Mean)31.46 USD
Target Range16.00 USD – 46.00 USD
# Analysts13
Ownership
Shares Out.65.70M
Float36.63M
Insiders10.22%
Institutions103.98%
Short Interest
Short Ratio19.3d
Short % Float20.94%
Short % Out.14.99%
Shares Short9.85M
Short (prev mo.)9.33M
Technical
SMA 5021.35 (-3.4%)
SMA 20017.16 (+20.1%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)448.11K
Avg Vol (10d)558.39K
Technical Indicators
RSI (14)50.1
MACD-0.1065
MACD Signal-0.1091
MACD Hist.+0.0027
BB Upper24.02 USD
BB Middle21.64 USD
BB Lower19.26 USD
BB Width22.01%
ATR (14)1.090 USD
Vol Ratio (20d)0.20x